Novel mavacamten had a big impact on quality of life in obstructive hypertrophic cardiomyopathy, according to a secondary analysis of the EXPLORER-HCM trial.
The cardiac myosin inhibitor improved Kansas City Cardiomyopathy Questionnaire (KCCQ) overall summary score by 9.1 points more than that seen with placebo over 30 weeks (mean 14.9 vs 5.4 points, P<0.001 for difference). A 5-point change in score is considered clinically significant.
Similar advantages were seen across all KCCQ subscores, reported John Spertus, MD, MPH, of Saint Luke's Mid America Heart Institute and the University of Missouri-Kansas City, at the virtual American College of Cardiology meeting and simultaneously in The Lancet.
Read the full Medpage Today article: Mavacamten Boosts Quality of Life in Hypertrophic Cardiomyopathy